[Antiangiogenic therapy].
Arias Barquet
L
L
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D005136:Eye Proteins / Q000378:metabolism; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D009414:Nerve Growth Factors / Q000378:metabolism; D010778:Photochemotherapy; D000069579:Ranibizumab; D015843:Serpins / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D000099174:Pigment Epithelium-Derived Factor
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D005136:Eye Proteins; D009414:Nerve Growth Factors; D000069579:Ranibizumab; D015843:Serpins; D042461:Vascular Endothelial Growth Factor A; D000099174:Pigment Epithelium-Derived Factor; C495058:pegaptanib